Novel quadrivalent meningococcal A, C, W-135 and Y glycoconjugate vaccine for the broader protection of adolescents and adults.
Meningococcal meningitis and septicemia are a persistent public health concern owing to the associated mortality and devastating long-term sequelae. People of all ages may be affected, with the disease burden being higher in at-risk groups. Vaccination is the most rational approach to the prevention of invasive meningococcal disease. A novel quadrivalent meningococcal (Men) serogroup A, C, W-135 and Y polysaccharide-protein conjugate vaccine (MenACWY-CRM), has recently been licensed for use in individuals aged at least 11 years old in the USA, Canada and Europe. One dose of MenACWY-CRM is well tolerated, and induces robust immunity to all constituent vaccine serogroups in 11-65 year old individuals. MenACWY-CRM was found to be noninferior to the quadrivalent meningococcal ACWY-diphtheria toxoid glycoconjugate vaccine, which is also licensed in the USA and Canada. In Europe, MenACWY-CRM is the first quadrivalent meningococcal glycoconjugate vaccine available to provide broader protection against Neisseria meningitidis serogroups A, C, W-135 and Y.
Department of Paediatrics, Mater Dei Hospital, Tal-Qroqq, Msida, Malta. dpace@go.net.mt
David
D
Pace
D000293:Adolescent; D000328:Adult; D000368:Aged; D002170:Canada / Q000453:epidemiology; D002648:Child; D002986:Clinical Trials as Topic; D005060:Europe / Q000453:epidemiology; D006801:Humans; D008585:Meningitis, Meningococcal / Q000453:epidemiology / Q000382:microbiology / Q000517:prevention & control; D008589:Meningococcal Infections / Q000453:epidemiology* / Q000382:microbiology / Q000517:prevention & control*; D022401:Meningococcal Vaccines / Q000008:administration & dosage* / Q000276:immunology*; D008875:Middle Aged; D009345:Neisseria meningitidis / Q000145:classification / Q000276:immunology*; D018805:Sepsis / Q000453:epidemiology / Q000382:microbiology / Q000517:prevention & control; D014481:United States / Q000453:epidemiology; D014611:Vaccination / Q000379:methods; D018074:Vaccines, Conjugate / Q000276:immunology; D055815:Young Adult
C556088:MenACWY-CRM vaccine; D022401:Meningococcal Vaccines; D018074:Vaccines, Conjugate